Introduction and marketing status of furosemide subcutaneous injection (furosemide)

1. Name: Furosemide Subcutaneous Injection, furosemide, FUROSCIX

2. Indications:

Furosemide subcutaneous injection (furosemide)-FUROSCIX is indicated for the treatment of congestion due to fluid overload in adults with chronic heart failure.

3. Usage and dosage:

1. Dosage:Disposable in-body infusion set with prefilled cartridge is preprogrammed to infuse 30 mg of furosemide at a rate of 12.5 mg per hour for the first hour and 12.5 mg of furosemide for the next 4 hours. Frusemide subcutaneous injection is not suitable for long-term use and should be replaced with oral diuretics as soon as possible.

2. Important Administration Instructions: Furosemide subcutaneous injection is intended for use in situations where patients can limit their activities during administration. Furosemide subcutaneous injection is not suitable for use in an MRI environment. Inspection before administrationFrusemide subcutaneous injection prefilled cartridge. Furosemide subcutaneous injection is a clear to slightly yellow solution. Do not use furosemide subcutaneous injection if the solution becomes discolored or cloudy.

3. How to use: Insert the pre-installed furosemide cartridge into the internal syringe and close the cartridge holder. Peel off the sticky padding from the intracorporeal syringe and apply it to a clean, dry area of u200bu200byour abdomen between the top of your waistline and the bottom of your ribcage that is not tender, bruised, red, or hard. The distance from the top of your waistline to the bottom of your rib cage should be at least 2 inches. Firmly press and release the blue start button to begin the injection. Do not withdraw until injection is complete (signaled by a steady green status light, a beep, and a white plunger rod filling the cartridge window). Rotate the location of each subcutaneous injection.

4. Adverse reactions:

Common adverse reactions observed during treatment with furosemide subcutaneous infusion set are administration site and skin reactions: erythema, bruising, edema, and infusion site pain; associated warnings and precautions include fluid, electrolyte, and metabolic abnormalities; worsening of renal function; ototoxicity; and acute urinary retention.

5. Supply and storage:

Frusemide Subcutaneous Injection is a sterile, clear to yellowish, pyrogen-free liquid provided in single-dose prefilled cartridges for subcutaneous infusion, packaged with an in vivo infusion set. Each single-use intracorporeal syringe with prefilled cartridge is designed for use in80 mg of furosemide in 10 mL of solution delivered over 5 hours, containing an 80 mg/10 mL prefilled cartridge in a carton packaged with an intracorporeal syringe

Furosemide SC solution may be stored between 20°C and 25°C (68°F and 77°F); tolerances are allowed between 15°C and 30°C (59°F and 86°F). Do not refrigerate or freeze. Protection from lightFrusemide subcutaneous injection. Do not remove box from carton until ready to use. Do not use if solution becomes discolored or cloudy. Protect the internal syringe from water.

6. Taboo:

Furosemide subcutaneous injection is contraindicated in anuric patients.

Furosemide is contraindicated in patients with a history of hypersensitivity to furosemide, any component of furosemide preparations, or medical adhesives.

This product is contraindicated in patients with liver cirrhosis.

7. Mechanism of action:

Furosemide primarily inhibits sodium and chloride reabsorption in the proximal and distal tubules and the loops of Hanle. The high degree of diuresis is primarily due to the unique site of action. The effect on the distal tubule is independent of any inhibition of carbonic anhydrase and aldosterone.

8. Listing situation:

Furosemide subcutaneous injection was approved by the U.S. National Drug Administration (FDA) for marketing in the United States on October 7, 2022, with the trade name FUROSCIX. There is no news of listing in China and other regions.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eac958dd-8d43-e44e-e053-2995a90a4d5e